Bringing the fundamentals into focus…
Back to Thermo Fisher Scientific Inc.
How Thermo Fisher Scientific Inc. stacks up
TMO · against 15 other Healthcare companies of similar size
Valuation
53/ 100
Near the bottom of its peers.
Ranked #12 of 16 · scores higher than 20% of peers
Bars: peers in each 10-point band of the valuation score5 peers with a valuation score of 50–59, including TMO · Click a bar to see the companies
Why valuation scores 53?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 4.0% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 2.7% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 66% of peers. Free cash flow yield: 2.8% vs peer median 0.0%
Metric by metric
Position: dot = TMO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TMO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 16 reported | 2.7% | 3.0% | 40% | 30% | |
| EBITDA yieldHigher is better · 16 reported | 4.0% | 6.4% | 7% | 50% | |
| Free cash flow yieldHigher is better · 15 reported | 2.8% | 4.1% | 21% | 20% | |
| Book yieldHigher is better · 15 reported | 20.4% | 15.1% | 71% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around TMO| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 177.5B USD | 92 | 71 | |
| 2 | 162.93T ARS (≈$162.9B) | 82 | 63 | |
| 3 | 317.9B CHF (≈$365.6B) | 70 | 60 | |
| 4 | 302.7B USD | 68 | 63 | |
| 5 | 285.2B USD | 66 | 63 | |
| 9 | 189.3B USD | 57 | 45 | |
| 10 | 134.5B USD | 55 | 70 | |
| 11 | 356.9B USD | 54 | 37 | |
| 12 | 161.8B USD | 53 | 50 | |
| 12 | 258.2B USD | 53 | 47 | |
| 14 | 505.4B USD | 48 | 53 | |
| 15 | 155.7B USD | 47 | 64 | |
| 16 | 207.7B USD | 8 | 18 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score